Should Upfront Therapy With Androgen Receptor Signaling Inhibitors Be Used in All Japanese Patients With Metastatic Castration-sensitive Prostate Cancer?
Upfront ARSI therapy for Japanese patients with mCSPC significantly extended the time to CRPC but did not demonstrate a benefit in OS compared to vintage hormonal therapy.
Authors
- Kuniaki Inoue (ORCID: https://orcid.org/0000-0002-4066-9951)
- SHUYA HIRAO
- Kiyohide Fujimoto (ORCID: https://orcid.org/0000-0003-1507-2464)
- Yukinari Hosokawa
- Keiichi Sakamoto
- Masaki Haramoto
- Kouji Iida (ORCID: https://orcid.org/0000-0002-3121-0655)
- Takanori Yoshida (ORCID: https://orcid.org/0000-0002-6261-6578)
- Toshihisa Saka
- Makito Miyake (ORCID: https://orcid.org/0000-0001-9503-7356)
- Mikiko Onishi
- Nobumichi Tanaka (ORCID: https://orcid.org/0000-0001-9242-7877)
- Yoshiaki Matsumura (ORCID: https://orcid.org/0000-0001-5873-0346)
- Shunsuke Hajikano
- Fumisato Maesaka (ORCID: https://orcid.org/0000-0001-7754-7184)
- Takashi Iwamoto (ORCID: https://orcid.org/0000-0003-3644-3121)
- Kenta Onishi (ORCID: https://orcid.org/0000-0003-1767-9905)
- Yasushi Nakai
- Yoshitaka Itami
- Yusuke Iemura
Institutions
- Osaka Ekisaikai Hospital (JP)
- Nara City Hospital (JP)
- Tane General Hospital (JP)
- Yamato Municipal Hospital (JP)
- Sendai Kousei Hospital (JP)
- Nara Medical University (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-11-29
- DOI
- https://doi.org/10.21873/anticanres.17894
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00